Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Ricavi netti consolidati per l’esercizio 2025 pari a € 2.618,4 milioni, +11,8% o +8,3% a perimetro omogeneo(3) e a cambi costantiEBITDA(1) pari a € 991,1 milioni, +14,5%, con un’incidenza sui ricavi...
-
RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA +14.5%, ADJUSTED NET INCOME +14.5%
-
Washington, D.C., Feb. 01, 2026 (GLOBE NEWSWIRE) -- Rare disease patients often have to make 17 medical visits before a diagnosis. Under the theme of Early Detection Drives Direction, Global Liver...
-
South San Francisco, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- The California Institute for Regenerative Medicine (CIRM) has approved a new funding program to accelerate therapies for rare diseases,...
-
SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
-
Seamless Therapeutics announces research collaboration and licensing agreement with Eli Lilly for gene therapy for genetic hearing disorders
-
Avance Clinical will meet biotech sponsors at Biotech Showcase 2026 in San Francisco, highlighting the launch of the new Early Phase Center of Excellence.
-
AUSTIN, Texas, Dec. 02, 2025 (GLOBE NEWSWIRE) -- BioMedWire: Chronic conditions and rare diseases in the aging population present an urgent and expanding challenge within the U.S. healthcare system,...
-
SAN JOSE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
-
– Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics – – Completed $60.3 million oversubscribed private placement led by Samsara...